1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Nuclear Medicine/ Radiopharmaceuticals Market
2.2. Global Nuclear Medicine/ Radiopharmaceuticals Market, By Type, 2023 (US$ Million)
2.3. Global Nuclear Medicine/ Radiopharmaceuticals Market, By Application, 2023 (US$ Million)
2.4. Global Nuclear Medicine/ Radiopharmaceuticals Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Nuclear Medicine/ Radiopharmaceuticals Market: Competitive Analysis
3.1. Market Positioning of Key Nuclear Medicine/ Radiopharmaceuticals Market Vendors
3.2. Strategies Adopted by Nuclear Medicine/ Radiopharmaceuticals Market Vendors
3.3. Key Industry Strategies
4. Nuclear Medicine/ Radiopharmaceuticals Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Nuclear Medicine/ Radiopharmaceuticals Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Diagnostics radiopharmaceuticals
5.3.1.1. SPECT Radiopharmaceuticals
5.3.1.1.1. Iodine-123
5.3.1.1.2. Technetium-99m
5.3.1.1.3. Xenon-133
5.3.1.1.4. Thallium-201
5.3.1.1.5. Fluorine-18
5.3.1.1.6. Gallium-67
5.3.1.1.7. Other SPECT Isotopes
5.3.1.2. PET Radiopharmaceuticals
5.3.1.2.1. Rubidium 82
5.3.1.2.2. Fluorine 18
5.3.1.2.3. Other PET Radiopharmaceutical
5.3.2. Therapeutic radiopharmaceuticals
5.3.2.1. Beta Emitters
5.3.2.1.1. Iodine 131
5.3.2.1.2. Iodine 131
5.3.2.1.3. Strontium 89
5.3.2.1.4. Yttrium 90
5.3.2.1.5. Samarium 153
5.3.2.1.6. Rhenium 186/188
5.3.2.1.7. Lutetium-177
5.3.2.1.8. Other Beta Emitters
5.3.2.2. Alfa Emitter
5.3.2.2.1. Radium 223
5.3.2.2.2. Bismuth 213
5.3.2.2.3. Other Beta Emitter
5.3.2.3. Brachytherapy
5.3.2.3.1. Iridium -192
5.3.2.3.2. Palladium-103
5.3.2.3.3. Iodine-125
5.3.2.3.4. Cesium-131

6. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Therapeutic
6.3.1.1. Thyroid
6.3.1.2. Oncology
6.3.1.3. Bone Metastasis
6.3.1.4. Other Therapeutic Application
6.3.2. Diagnostic Application
6.3.2.1. Cardiology
6.3.2.2. Thyroid
6.3.2.3. Oncology
6.3.2.4. Other Therapeutic Application


7. North America Nuclear Medicine/ Radiopharmaceuticals Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
7.3. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
7.4.Nuclear Medicine/ Radiopharmaceuticals Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
7.4.1.1.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
7.4.1.2.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
7.4.1.3.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)

8. UK and European Union Nuclear Medicine/ Radiopharmaceuticals Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
8.3. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
8.4.Nuclear Medicine/ Radiopharmaceuticals Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
8.4.1.1.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
8.4.1.2.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
8.4.1.3.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
8.4.1.4.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
8.4.1.5.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
8.4.1.6.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)

9. Asia Pacific Nuclear Medicine/ Radiopharmaceuticals Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
9.3. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
9.4.Nuclear Medicine/ Radiopharmaceuticals Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
9.4.1.1.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
9.4.1.2.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
9.4.1.3.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
9.4.1.4.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
9.4.1.5.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
9.4.1.6.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)

10. Latin America Nuclear Medicine/ Radiopharmaceuticals Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
10.3. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
10.4.Nuclear Medicine/ Radiopharmaceuticals Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
10.4.1.1.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
10.4.1.2.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
10.4.1.3.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)

11. Middle East and Africa Nuclear Medicine/ Radiopharmaceuticals Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
11.3. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
11.4.Nuclear Medicine/ Radiopharmaceuticals Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
11.4.1.1.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
11.4.1.2.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Nuclear Medicine/ Radiopharmaceuticals Market: By Type, 2022-2032, USD (Million)
11.4.1.3.2. Nuclear Medicine/ Radiopharmaceuticals Market: By Application, 2022-2032, USD (Million)

12. Company Profile
12.1. Advanced Accelerator Applications S.A.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Bayer AG
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Bracco Imaging S.p.A
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Cardinal Health, Inc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. GE Healthcare
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. IBA Molecular Imaging
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Lantheus Medical Imaging Inc.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Mallinckrodt plc.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Medtronic, plc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Nordion, Inc.
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. NTP Radioisotopes SOC Ltd.
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Segami Corporation
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives